1001646-85-0

Basic information

• Product Name: (R)-1-BOC-4-(3-CBZ-AMINO-3-METHOXYCARBONYL-PROPYL)PIPERIDINE
• Synonyms: (R)-1-BOC-4-(3-CBZ-AMINO-3-METHOXYCARBONYL-PROPYL)PIPERIDINE;(R)-4-(3-BENZYLOXYCARBONYLAMINO-3-METHOXYCARBONYL-PROPYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• CAS NO: 1001646-85-0
• Molecular Formula: C₂₃H₃₄N₂O₆
• Molecular Weight: 434.52586
• Mol File: 1001646-85-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-1-BOC-4-(3-CBZ-AMINO-3-METHOXYCARBONYL-PROPYL)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-BOC-4-(3-CBZ-AMINO-3-METHOXYCARBONYL-PROPYL)PIPERIDINE(1001646-85-0)
• EPA Substance Registry System: (R)-1-BOC-4-(3-CBZ-AMINO-3-METHOXYCARBONYL-PROPYL)PIPERIDINE(1001646-85-0)

Safety Data

• Hazardous Substances Data: 1001646-85-0(Hazardous Substances Data)

Usage

General Description

(R)-1-BOC-4-(3-CBZ-amino-3-methoxycarbonyl-propyl)piperidine is a compound composed of a piperidine core substituted with a BOC (tert-butyloxycarbonyl) group and a 3-CBZ (benzyloxycarbonyl) amino group. Additionally, there is a 3-methoxycarbonyl-propyl substituent attached to the amino group. (R)-1-BOC-4-(3-CBZ-AMINO-3-METHOXYCARBONYL-PROPYL)PIPERIDINE is often used as a reagent in chemical synthesis, particularly in the field of pharmaceuticals. It is utilized in the production of new drug candidates and as a building block for the construction of more complex molecules. Its unique structure and reactivity make it a valuable tool in organic chemistry research and drug development.

Upstream product

• 890849-78-2 C₂₃H₃₂N₂O₆ 
• 871675-56-8 4-(3-benzyloxycarbonylamino-3-methoxycarbonyl-allyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.

COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.